The effects of systemic cyclosporine in acute Stevens-Johnson syndrome/toxic epidermal necrolysis on ocular disease.
Cyclosporine
Ocular surface disease
Stevens-johnson syndrome
Toxic epidermal necrolysis
Journal
The ocular surface
ISSN: 1937-5913
Titre abrégé: Ocul Surf
Pays: United States
ID NLM: 101156063
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
17
06
2019
revised:
09
04
2020
accepted:
05
05
2020
pubmed:
24
5
2020
medline:
25
6
2021
entrez:
24
5
2020
Statut:
ppublish
Résumé
To evaluate the effect of systemic cyclosporine (CsA) on ocular disease in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) patients. In this retrospective, comparative cohort study at a single center, patients with a diagnosis of SJS/TEN and with at least 3 months of follow up were divided into two groups: those who received systemic CsA and those who did not receive systemic CsA. Best-corrected visual acuity (BCVA) and chronic ocular surface complications score (COCS) at final follow-up were compared between the two groups. The median age and follow-up period of patients was 29 years (range, 1.5-71 years) and 16.8 months (range, 3.67-91.58 months), respectively. BCVA, COCS, meibomian gland dysfunction, limbal stem cell deficiency, and the need for mucous membrane grafting and scleral lenses were not significantly different between patients who received systemic CsA as compared to patients who did not receive systemic CsA. In this small cohort of patients with SJS/TEN, we could identify no association between the use of systemic CsA as a component of their initial therapy and chronic ocular complications.
Identifiants
pubmed: 32445836
pii: S1542-0124(20)30081-1
doi: 10.1016/j.jtos.2020.05.003
pmc: PMC7811361
mid: NIHMS1603383
pii:
doi:
Substances chimiques
Cyclosporine
83HN0GTJ6D
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
128-132Subventions
Organisme : NEI NIH HHS
ID : K23 EY028230
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Dermatol Ther. 2011 Mar-Apr;24(2):207-18
pubmed: 21410610
Ocul Surf. 2016 Apr;14(2):168-88
pubmed: 26882981
J Am Acad Dermatol. 2014 Nov;71(5):941-7
pubmed: 25087214
Cutis. 2011 Jan;87(1):24-9
pubmed: 21323097
Arch Ophthalmol. 1973 Nov;90(5):376-9
pubmed: 4746089
Eye (Lond). 2005 Aug;19(8):846-53
pubmed: 15389280
J Burn Care Rehabil. 2005 Jan-Feb;26(1):33-41
pubmed: 15640731
J Am Acad Dermatol. 2013 Aug;69(2):187.e1-16; quiz 203-4
pubmed: 23866879
Ophthalmology. 2007 Jul;114(7):1294-302
pubmed: 17475335
Br J Dermatol. 2010 Oct;163(4):847-53
pubmed: 20500799
Lancet. 1998 Nov 14;352(9140):1586-9
pubmed: 9843104
Ophthalmology. 2015 Feb;122(2):254-64
pubmed: 25262319
Allergy Proc. 1995 Jul-Aug;16(4):157-61
pubmed: 8566721
J Trauma. 2000 Mar;48(3):473-8
pubmed: 10744287
Br J Dermatol. 2005 Aug;153(2):241-53
pubmed: 16086734
Ophthalmology. 1995 Nov;102(11):1669-76
pubmed: 9098260
JAMA Dermatol. 2017 Jun 1;153(6):514-522
pubmed: 28329382
J Inflamm Res. 2018 Mar 28;11:135-142
pubmed: 29636627
J Ocul Pharmacol Ther. 2013 Apr;29(3):372-7
pubmed: 23289903
Indian J Dermatol Venereol Leprol. 2017 May-Jun;83(3):312-316
pubmed: 28366923
South Med J. 1980 May;73(5):599-602
pubmed: 7375977
Arch Dis Child. 1978 Jan;53(1):38-42
pubmed: 626517
Curr Opin Ophthalmol. 2016 Nov;27(6):522-529
pubmed: 27585215
Pediatr Dermatol. 2014 Jul-Aug;31(4):532-4
pubmed: 23072342
Dermatology. 2003;207(1):33-6
pubmed: 12835545